Acute ischaemic stroke Circulatory System Stroke
Conditions
Interventions
Two consecutive doses of EPO (5,000 IU each time, subcutaneously) administered at 48 hours and 72 hours after acute IS.
Sponsors
National Science Council (Taiwan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged greater than 45 years, either sex
Exclusion criteria
Exclusion criteria: Patients with history of the followings were excluded from the study: 1. Intracranial haemorrhage 2. Surgery or trauma within the preceding 3 months 3. Abnormal liver function 4. Haematology disorders 5. Renal insufficiency (serum creatinine greater than 1.5 mg/dL) 6. Malignancy 7. Febrile disorders 8. Acute or chronic inflammatory disease at study entry 9. Liver cirrhosis 10. Atrial fibrillation 11. Congestive heart failure 12. Contraindications for magnetic resonance imaging (MRI) examination 13. No evidence of acute IS by MRI study 14. Myeloproliferative disorder 15. Antibodies or being allergic to EPO 16. Pregnancy 17. Haemoglobin level greater than 15.0 g/dL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90-day combined major adverse neurological event (MANE) defined as: 1. Recurrent stroke 2. National Institutes of Health Stroke Scale (NIHSS) greater than or equal to 8 3. Death | — |
Secondary
| Measure | Time frame |
|---|---|
| To establish the time course of circulating level of EPCs in patients after acute IS and the ability of two doses of EPO in enhancing circulating EPC level | — |
Countries
Taiwan
Outcome results
None listed